Cornea, External Disease and Refractive Surgery, Department of Ophthalmology, University of Florida, College of Medicine, Gainesville, Florida.
Digit J Ophthalmol. 2022 Jun 27;28(8):34-37. doi: 10.5693/djo.02.2022.02.002. eCollection 2022.
Netarsudil is a relatively new medication for the treatment of primary open-angle glaucoma and ocular hypertension. It has been associated with red eyes and burning after instillation. Reticular epitheliopathy is a relatively rare complication of netarsudil that has been described in patients with preexisting corneal edema. We report the case of a healthy 76-year-old woman who developed reticular epitheliopathy after full-thickness penetrating keratoplasty that completely resolved following discontinuation of the medication. In cases where netarsudil is initiated for treatment of glaucoma or, off-label, endothelial dysfunction, reticular epithelial edema should be considered in patients complaining of a decline in vision and severe pain.
奈他舒地尔是一种用于治疗原发性开角型青光眼和高眼压症的新型药物。它与滴注后眼红和灼热感有关。网状层上皮病是奈他舒地尔一种相对罕见的并发症，已在存在角膜水肿的患者中描述过。我们报告了一例健康的 76 岁女性，她在全层穿透性角膜移植术后出现网状层上皮病，停药后完全消退。在因治疗青光眼或非适应证的内皮功能障碍而开始使用奈他舒地尔后，如果患者出现视力下降和严重疼痛，应考虑网状层上皮水肿。
